This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Treatment With MK0966 for the Prevention of Prostate Cancer (0966-201)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT00060476
First received: May 6, 2003
Last updated: May 5, 2017
Last verified: May 2017
May 6, 2003
May 5, 2017
January 8, 2003
December 8, 2004   (Final data collection date for primary outcome measure)
Time to prostate cancer [ Time Frame: Duration of Treatment ]
Not Provided
Complete list of historical versions of study NCT00060476 on ClinicalTrials.gov Archive Site
Time to aggressive prostate cancer [ Time Frame: Duration of Treatment ]
Not Provided
Not Provided
Not Provided
 
Treatment With MK0966 for the Prevention of Prostate Cancer (0966-201)
A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Effects of Rofecoxib in Decreasing the Risk of Prostate Cancer (ViP Study)
To determine the efficacy and safety of an investigational compound (MK0966) for the prevention of prostate cancer.
The duration of treatment is 6 years.
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Investigator
Primary Purpose: Prevention
Prostate Cancer
  • Drug: rofecoxib
    Other Name: MK0966
  • Drug: Comparator: placebo (unspecified)
Not Provided
van Adelsberg J, Gann P, Ko AT, Damber JE, Logothetis C, Marberger M, Schmitz-Drager BJ, Tubaro A, Harms CJ, Roehrborn C. The VIOXX in Prostate Cancer Prevention study: cardiovascular events observed in the rofecoxib 25 mg and placebo treatment groups. Curr Med Res Opin. 2007 Sep;23(9):2063-70.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
15000
December 8, 2004
December 8, 2004   (Final data collection date for primary outcome measure)
Regular PSA testing and study biopsies required.
Sexes Eligible for Study: Male
50 Years to 75 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
Puerto Rico,   United States
 
NCT00060476
0966-201
Formally-P30A03LD
MK0966-201
2006_414
Not Provided
Not Provided
Not Provided
Not Provided
Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
Not Provided
Study Director: Medical Monitor Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
May 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP